Compare UTMD & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UTMD | EMBC |
|---|---|---|
| Founded | 1978 | 1924 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 226.1M | 199.9M |
| IPO Year | 1994 | 2021 |
| Metric | UTMD | EMBC |
|---|---|---|
| Price | $72.77 | $5.05 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $18.50 |
| AVG Volume (30 Days) | 21.7K | ★ 1.6M |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | 1.91% | ★ 6.88% |
| EPS Growth | N/A | ★ 20.90 |
| EPS | ★ 1.66 | 1.03 |
| Revenue | ★ $38,520,000.00 | N/A |
| Revenue This Year | N/A | $1.17 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $43.25 | ★ $4.83 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $53.66 | $2.77 |
| 52 Week High | $75.75 | $15.55 |
| Indicator | UTMD | EMBC |
|---|---|---|
| Relative Strength Index (RSI) | 56.15 | 64.13 |
| Support Level | $68.93 | $3.01 |
| Resistance Level | $74.75 | $5.63 |
| Average True Range (ATR) | 1.53 | 0.28 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 71.01 | 49.25 |
Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.